Introduction: <i>Standards of Medical Care in Diabetes—2022</i>

,

doi:10.2337/dc22-sint

Cited by 297 publications

(211 citation statements)

References 4 publications

Supporting

Mentioning

162

Contrasting

Unclassified

Order By: Relevance

“…In this study, participants were asked to engage at least once per week with their health coach or care team and to participate in a telemedicine consultation with an Onduo endocrinologist. All participants were mailed a RT-CGM device (Dexcom G6, Dexcom) for intermittent use as indicated in the American Diabetes Association (ADA) Standards of Medical Care in Diabetes for adults with T2D [ 16 ]. Participants were asked to wear six 10-day sensors, with an initial period of 20 days (2 sensors); the remaining 4 sensors were worn on a 10-day “on” and 11-day “off” cycle.…”

Section: Methodsmentioning

confidence: 99%

“…CGM glucose data were used by the care team for education and lifestyle coaching on the impact of diet and exercise and by the Onduo endocrinologists for medication management and to evaluate the efficacy of medication changes on glycemic control. Optimization of medication regimens was done remotely by endocrinologists and incorporated medical history, laboratory test results, and patient preferences, and was done in accordance with the ADA Standards, which is analogous to an in-person clinical practice [ 16 ]. The ADA Standards indicate that glucagon-like peptide-1 (GLP-1) receptor agonists are recommended as the first injectable medication, preferable to insulin.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study

Majithia¹,

Erani²,

Kusiak³

et al. 2022

JMIR Form Res

View full text Add to dashboard Cite

Background The Onduo virtual care program for people with type 2 diabetes (T2D) includes a mobile app, remote lifestyle coaching, connected devices, and telemedicine consultations with endocrinologists for medication management and prescription of real-time continuous glucose monitoring (RT-CGM) devices. In a previously described 4-month prospective study of this program, adults with T2D and baseline glycated hemoglobin (HbA1c) ≥8.0% to ≤12.0% experienced a mean HbA1c decrease of 1.6% with no significant increase in hypoglycemia. Objective The objective of this analysis was to evaluate medication optimization and management in the 4-month prospective T2D study. Methods Study participants received at least 1 telemedicine consultation with an Onduo endocrinologist for diabetes medication management and used RT-CGM intermittently to guide therapy and dosing. Medication changes were analyzed. Results Of 55 participants, 48 (87%) had a medication change consisting of a dose change, addition, or discontinuation. Of these, 15 (31%) participants had a net increase in number of diabetes medication classes from baseline. Mean time to first medication change for these participants was 36 days. The percentage of participants taking a glucagon-like peptide-1 receptor agonist increased from 25% (12/48) to 56% (n=27), while the percentages of participants taking a sulfonylurea or dipeptidyl peptidase 4 inhibitor decreased from 56% (n=27) to 33% (n=16) and 17% (n=8) to 6% (n=3), respectively. Prescriptions of other antidiabetic medication classes including insulin did not change significantly. Conclusions The Onduo virtual care program can play an important role in providing timely access to guideline-based diabetes management medications and technologies for people with T2D. Trial Registration ClinicalTrials.gov NCT03865381; https://clinicaltrials.gov/ct2/show/NCT03865381

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study

Majithia¹,

Erani²,

Kusiak³

et al. 2022

JMIR Form Res

View full text Add to dashboard Cite

show abstract

“…Diabetes Mellitus (DM) is a metabolic disorder characterized by the presence of hyperglycemia due to defects in insulin secretion, insulin action, or both [1]. The complications of DM include nephropathy, neuropathy, retinopathy, foot damage, skin conditions, increased risk of cardiovascular disease, and dementia, to name a few.…”

Section: Introductionmentioning

confidence: 99%

Progress of Polyaniline Glucose Sensors for Diabetes Mellitus Management Utilizing Enzymatic and Non-Enzymatic Detection

et al. 2022

View full text Add to dashboard Cite

Glucose measurement is a fundamental tool in the daily care of Diabetes Mellitus (DM) patients and healthcare professionals. While there is an established market for glucose sensors, the rising number of DM cases has promoted intensive research to provide accurate systems for glucose monitoring. Polyaniline (PAni) is a conductive polymer with a linear conjugated backbone with sequences of single C–C and double C=C bonds. This unique structure produces attractive features for the design of sensing systems such as conductivity, biocompatibility, environmental stability, tunable electrochemical properties, and antibacterial activity. PAni-based glucose sensors (PBGS) were actively developed in past years, using either enzymatic or non-enzymatic principles. In these devices, PAni played roles as a conductive material for electron transfer, biocompatible matrix for enzymatic immobilization, or sensitive layer for detection. In this review, we covered the development of PBGS from 2015 to the present, and it is not even exhaustive; it provides an overview of advances and achievements for enzymatic and non-enzymatic PBGB PBGS for self-monitoring and continuous blood glucose monitoring. Additionally, the limitations of PBGB PBGS to advance into robust and stable technology and the challenges associated with their implementation are presented and discussed.

show abstract

“…The American Diabetes Association (ADA) releases updated Standards of Medical Care in Diabetes every year in January [ 24 ]. Recent updates have focused on individualization of diabetes management in screening, intervention and care, use of technology, and prevention of complications [ 25 ].…”

Section: Standards Of Medical Care In Diabetes Of the American Diabet...mentioning

confidence: 99%

“…The JDS guideline recommends that glucose-lowering agents are to be chosen in light of their pharmacological and side effect profiles to address each patient’s disease condition. There is no priority recommendation for any class of glucose-lowering agents [ 24 ]. The JDS guideline emphasizes that the pathophysiology of DM and metformin doses differ in Japanese people, whereas the results for metformin are primarily from trials in Europe and the USA [ 67 ].…”

Section: Japanese Clinical Practice Guideline For Diabetes 2019mentioning

confidence: 99%

Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus

Lee

Kim

2022

Endocrinol Metab

View full text Add to dashboard Cite

Guidelines for the management of patients with diabetes have become an important part of clinical practice that improve the quality of care and help establish evidence-based medicine in this field. With rapidly accumulating evidence on various aspects of diabetes care, including landmark clinical trials of treatment agents and newer technologies, timely updates of the guidelines capture the most current state of the field and present a consensus. As a leading academic society, the Korean Diabetes Association publishes practice guidelines biennially and the American Diabetes Association does so annually. In this review, we summarize the key changes suggested in the most recent guidelines. Some of the important updates include treatment algorithms emphasizing comorbid conditions such as atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease in the selection of anti-diabetic agents; wider application of continuous glucose monitoring (CGM), insulin pump technologies and indices derived from CGM such as time in range; more active screening of subjects at high-risk of diabetes; and more detailed individualization in diabetes care. Although there are both similarities and differences among guidelines and some uncertainty remains, these updates provide a good approach for many clinical practitioners who are battling with diabetes.

show abstract

Introduction: Standards of Medical Care in Diabetes—2022

Abstract: ADA statements undergo a formal review process, including a review by the appropriate ADA national committee, ADA science and health care staff, and the ADA's Board of Directors.

Cited by 297 publications

References 4 publications

Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study

Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study

Progress of Polyaniline Glucose Sensors for Diabetes Mellitus Management Utilizing Enzymatic and Non-Enzymatic Detection

Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus

Contact Info

Product

Resources

About